{"id":1001052,"date":"2026-09-08T07:15:50","date_gmt":"2026-09-08T11:15:50","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-host-obexelimab-igg4-rd-investor-event\/"},"modified":"2026-09-08T07:15:50","modified_gmt":"2026-09-08T11:15:50","slug":"zenas-biopharma-to-host-obexelimab-igg4-rd-investor-event","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-host-obexelimab-igg4-rd-investor-event\/","title":{"rendered":"Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event"},"content":{"rendered":"
\n

WALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (\u201cZenas\u201d or the \u201cCompany\u201d) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced that it will host an Obexelimab IgG4-RD Investor Event virtually on Tuesday, September 29, 2026, from 8:00 \u2013 9:30 a.m. ET.<\/p>\n

Zenas\u2019 management team will be joined by Guy Katz, M.D., Division of Rheumatology, Inflammation, and Immunity, Massachusetts General Hospital, Boston, MA, USA. The event will provide an overview of Immunoglobulin G4-Related Disease (IgG4-RD), including current management strategies, and the unmet need of people living with this disease. Management will also provide an update on the Company\u2019s prelaunch preparedness strategies and the potential commercial opportunity for obexelimab for IgG4-RD, if approved by the U.S. Food and Drug Administration (FDA).<\/p>\n

In August 2026, the FDA accepted the Company\u2019s Biologics License Application (BLA) for obexelimab for the treatment of IgG4-RD. The BLA has a Prescription Drug User Fee Act (PDUFA) target action date of May 27, 2027. Zenas expects to submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in the second half of 2026.<\/p>\n

\n Conference Call Information
<\/strong>To access the live webcast of the call, please visit the \u201cEvents and Presentations<\/a>\u201d page in the Investor & Media Relations<\/a> section of the Zenas BioPharma website<\/a>. A replay of the webcast will be available following the call.<\/p>\n

\n About Zenas BioPharma, Inc.
<\/strong>Zenas is a clinical-stage global biopharmaceutical company focused on the development and commercialization of therapies for autoimmune diseases and inflammatory conditions. Zenas combines our experienced leadership team with a disciplined global product candidate acquisition approach to identify, acquire and develop product candidates with the potential to deliver clinically meaningful benefits to patients. Zenas is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, Zenas\u2019 lead product candidate, is a bifunctional monoclonal antibody designed to bind CD19 and Fc\u03b3RIIb to inhibit the activity of B cells implicated in many autoimmune diseases without depleting them. Zenas believes that the unique mechanism of action of obexelimab and its self-administered, subcutaneous injection regimen may enable sustained control across multiple chronic autoimmune diseases. Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule BTK inhibitor. Orelabrutinib\u2019s mechanism of action targets pathogenic B cells not only in the periphery but also within the CNS. Additionally, it directly modulates macrophages and microglial cells in the CNS, with the potential to address compartmentalized inflammation and disease progression in MS. Zenas\u2019 earlier stage programs include ZB021, a novel, potentially best-in-class, oral, IL-17AA\/AF inhibitor, ZB022, a preclinical, potentially best-in-class, oral, brain-penetrant, TYK2 inhibitor, and ZB014, a preclinical, half-life extended anti-CD19 and Fc\u03b3RIIb monoclonal antibody. For more information about Zenas BioPharma, please visit\u00a0https:\/\/zenasbio.com\/<\/a>\u00a0and follow us on\u00a0LinkedIn<\/a>.<\/p>\n

\n Zenas BioPharma Forward-Looking Statements
<\/strong>This press release contains \u201cforward-looking statements\u201d which involve risks, uncertainties and contingencies, many of which are beyond the control of the Company, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by terms such as \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201ccould,\u201d \u201cintend,\u201d \u201ctarget,\u201d \u201cproject,\u201d \u201ccontemplate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cpotential\u201d or \u201ccontinue\u201d or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward looking statements include, but are not limited to, the timing of and our ability to obtain FDA approval, and the timing of our submission of a MAA to the EMA for obexelimab in IgG4-RD. The forward-looking statements in this press release speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions that could cause the Company\u2019s actual results to differ materially from those anticipated in the forward-looking statements, including, but not limited to: the Company\u2019s limited operating history, incurrence of substantial losses since the Company\u2019s inception and anticipation of incurring substantial and increasing losses for the foreseeable future; the Company\u2019s need for substantial additional financing to achieve the Company\u2019s goals; the uncertainty of clinical development, which is lengthy and expensive, and characterized by uncertain outcomes, and risks related to additional costs or delays in completing, or failing to complete, the development and commercialization of the Company\u2019s current product candidates or any future product candidates; delays or difficulties in the enrollment and dosing of patients in clinical trials; the impact of any significant adverse events or undesirable side effects caused by the Company\u2019s product candidates; potential competition, including from large and specialty pharmaceutical and biotechnology companies, many of which already have approved therapies in the Company\u2019s current indications; the Company\u2019s ability to realize the benefits of the Company\u2019s current or future collaborations or licensing arrangements and ability to successfully consummate future partnerships; the Company\u2019s ability to obtain regulatory approval to commercialize any product candidate in the United States or any other jurisdiction; the risk that the data from our clinical trials is not sufficient to the satisfaction of the FDA or comparable foreign regulatory authorities to support the submission of a biologics license application or other comparable submission or to obtain regulatory approval for our product candidates for which we seek approval in the U.S. or elsewhere, and the risk that any such approval may be for a more narrow indication than the Company seeks; the Company\u2019s dependence on the services of the Company\u2019s senior management and other clinical and scientific personnel, and the Company\u2019s ability to retain these individuals or recruit additional management or clinical and scientific personnel; the Company\u2019s ability to grow the Company\u2019s organization, and manage the Company\u2019s growth and expansion of the Company\u2019s operations; risks related to the manufacturing of the Company\u2019s product candidates, which is complex, and the risk that the Company\u2019s third-party manufacturers may encounter difficulties in production; the Company\u2019s ability to obtain and maintain sufficient intellectual property protection for the Company\u2019s product candidates or any future product candidates the Company may develop; the Company\u2019s reliance on third parties to conduct the Company\u2019s preclinical studies and clinical trials; the Company\u2019s compliance with the Company\u2019s obligations under the licenses granted to the Company by others, for the rights to develop and commercialize the Company\u2019s product candidates; significant political, trade, and regulatory developments, including changes in relations between the U.S. and China; risks related to the operations of the Company\u2019s suppliers, many of which are located outside of the United States, including the Company\u2019s current sole contract manufacturing organization for obexelimab drug substance and drug product, WuXi Biologics (Hong Kong) Limited, and our partner, InnoCare, both of which are located in China; the risk that the Company\u2019s indebtedness resulting from the Company\u2019s loan agreement with Pharmakon Advisors LP, and the guarantors party to such agreement, or future indebtedness could adversely affect the Company\u2019s financial condition or restrict the Company\u2019s future operations; and other risks and uncertainties described in the section \u201cRisk Factors\u201d in the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2025, and Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, as well as other information we file with the Securities and Exchange Commission. The forward-looking statements in this press release are inherently uncertain, speak only as of the date of this press release and may prove incorrect. These statements are based upon information available to the Company as of the date of this press release and while the Company believes such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that the Company has conducted an exhaustive inquiry into, or review of, all potentially available relevant information. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond the Company\u2019s control, these forward-looking statements should not be relied upon as guarantees of future events. The events and circumstances reflected in the forward-looking statements may not be achieved or occur and actual future results, levels of activity, performance and events and circumstances could differ materially from those projected in the forward-looking statements. Moreover, the Company operates in an evolving environment. New risks and uncertainties may emerge from time to time, and management cannot predict all risks and uncertainties. Except as required by applicable law, the Company does not undertake to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.<\/p>\n

The Zenas BioPharma word mark, logo mark, and the \u201clightning bolt\u201d design are trademarks of Zenas BioPharma, Inc. or its affiliated companies. All rights reserved.<\/p>\n

\n Contacts:<\/strong>\n <\/p>\n

\n Investors:<\/strong>
\n
Argot Partners
Zenas@argotpartners.com<\/a><\/p>\n

\n Media:<\/strong>
\n
Kristin Ainsworth
SVP, U.S. Commercial Strategy & Corporate Affairs
612.839.6748<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

WALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (\u201cZenas\u201d or the \u201cCompany\u201d) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced that it will host an Obexelimab IgG4-RD Investor Event virtually on Tuesday, September 29, 2026, from 8:00 \u2013 9:30 a.m. ET. Zenas\u2019 management team will be joined by Guy Katz, M.D., Division of Rheumatology, Inflammation, and Immunity, Massachusetts General Hospital, Boston, MA, USA. The event will provide an overview of Immunoglobulin G4-Related Disease (IgG4-RD), including current management strategies, and the unmet need of people living with this disease. Management will also provide an update on … <\/p>\n

Continue reading “Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1001052","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nZenas BioPharma to Host Obexelimab IgG4-RD Investor Event - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-host-obexelimab-igg4-rd-investor-event\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (\u201cZenas\u201d or the \u201cCompany\u201d) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced that it will host an Obexelimab IgG4-RD Investor Event virtually on Tuesday, September 29, 2026, from 8:00 \u2013 9:30 a.m. ET. Zenas\u2019 management team will be joined by Guy Katz, M.D., Division of Rheumatology, Inflammation, and Immunity, Massachusetts General Hospital, Boston, MA, USA. The event will provide an overview of Immunoglobulin G4-Related Disease (IgG4-RD), including current management strategies, and the unmet need of people living with this disease. Management will also provide an update on … Continue reading "Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-host-obexelimab-igg4-rd-investor-event\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-08T11:15:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMjQ5NSM3ODIxMzEwIzIyMDc3OTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zenas-biopharma-to-host-obexelimab-igg4-rd-investor-event\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zenas-biopharma-to-host-obexelimab-igg4-rd-investor-event\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event\",\"datePublished\":\"2026-09-08T11:15:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zenas-biopharma-to-host-obexelimab-igg4-rd-investor-event\\\/\"},\"wordCount\":1531,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zenas-biopharma-to-host-obexelimab-igg4-rd-investor-event\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyMjQ5NSM3ODIxMzEwIzIyMDc3OTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zenas-biopharma-to-host-obexelimab-igg4-rd-investor-event\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zenas-biopharma-to-host-obexelimab-igg4-rd-investor-event\\\/\",\"name\":\"Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zenas-biopharma-to-host-obexelimab-igg4-rd-investor-event\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zenas-biopharma-to-host-obexelimab-igg4-rd-investor-event\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyMjQ5NSM3ODIxMzEwIzIyMDc3OTU=\",\"datePublished\":\"2026-09-08T11:15:50+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zenas-biopharma-to-host-obexelimab-igg4-rd-investor-event\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zenas-biopharma-to-host-obexelimab-igg4-rd-investor-event\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zenas-biopharma-to-host-obexelimab-igg4-rd-investor-event\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyMjQ5NSM3ODIxMzEwIzIyMDc3OTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyMjQ5NSM3ODIxMzEwIzIyMDc3OTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zenas-biopharma-to-host-obexelimab-igg4-rd-investor-event\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-host-obexelimab-igg4-rd-investor-event\/","og_locale":"en_US","og_type":"article","og_title":"Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event - Market Newsdesk","og_description":"WALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (\u201cZenas\u201d or the \u201cCompany\u201d) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced that it will host an Obexelimab IgG4-RD Investor Event virtually on Tuesday, September 29, 2026, from 8:00 \u2013 9:30 a.m. ET. Zenas\u2019 management team will be joined by Guy Katz, M.D., Division of Rheumatology, Inflammation, and Immunity, Massachusetts General Hospital, Boston, MA, USA. The event will provide an overview of Immunoglobulin G4-Related Disease (IgG4-RD), including current management strategies, and the unmet need of people living with this disease. Management will also provide an update on … Continue reading \"Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-host-obexelimab-igg4-rd-investor-event\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-08T11:15:50+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMjQ5NSM3ODIxMzEwIzIyMDc3OTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-host-obexelimab-igg4-rd-investor-event\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-host-obexelimab-igg4-rd-investor-event\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event","datePublished":"2026-09-08T11:15:50+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-host-obexelimab-igg4-rd-investor-event\/"},"wordCount":1531,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-host-obexelimab-igg4-rd-investor-event\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMjQ5NSM3ODIxMzEwIzIyMDc3OTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-host-obexelimab-igg4-rd-investor-event\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-host-obexelimab-igg4-rd-investor-event\/","name":"Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-host-obexelimab-igg4-rd-investor-event\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-host-obexelimab-igg4-rd-investor-event\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMjQ5NSM3ODIxMzEwIzIyMDc3OTU=","datePublished":"2026-09-08T11:15:50+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-host-obexelimab-igg4-rd-investor-event\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-host-obexelimab-igg4-rd-investor-event\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-host-obexelimab-igg4-rd-investor-event\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMjQ5NSM3ODIxMzEwIzIyMDc3OTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMjQ5NSM3ODIxMzEwIzIyMDc3OTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zenas-biopharma-to-host-obexelimab-igg4-rd-investor-event\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1001052","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1001052"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1001052\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1001052"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1001052"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1001052"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}